Such an addiction is neatly illustrated in chronic myeloid leukemia (CML) patients carrying BCR-ABL chimeric genes caused by translocations that can be effectively inhibited with BCR-ABL tyrosine kinase inhibitors like imatinib [96]. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.